ArticleCureus2025
A Dose of Smart Medicine to Make America Healthy Again: A $1 Trillion Win for Health, Innovation, and the Nation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smart medicines are FDA-regulated, evidence-based, smartphone-delivered treatments used alone or alongside drugs. Unlike general health apps, these prescription digital therapeutics are authorized to make treatment claims and are already in use for conditions such as migraine (CT-132), insomnia (Somryst), and major depressive disorder (Rejoyn). They are poised to transform American healthcare. By delivering precision interventions directly into patients' daily lives, they reduce the chronic disease burden, improve outcomes, and lower costs at scale. Drawing from my experience treating diverse populations across America, training future clinicians, shaping drug formularies, and developing digital therapeutics, I argue that smart medicine is the most promising lever for national health reform. If widely adopted in 2025, these technologies could save over $1 trillion annually while advancing healthcare access, restoring individual productivity, and reasserting U.S. leadership in medical innovation. Aligned with the goals of the Make America Healthier Again (MAHA) initiative, smart medicines support every major U.S. Department of Health and Human Services (HHS) priority, improving access, equity, and affordability of healthcare services for chronic diseases, behavioral health, and maternal care, and are thus uniquely positioned to close systemic healthcare gaps. This editorial proposes a federal initiative, Operation Smart Medicine, to accelerate the development, reimbursement, and nationwide deployment of smart medicines. Modeled on successful U.S. programs like Operation Warp Speed for COVID-19 and the HITECH Act for electronic health records, this initiative would enable smart medicines to support HHS/MAHA priorities and deliver scalable, value-based care. The technology exists, the evidence is emerging, and the time to align innovation with implementation is now.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.